India's Nafithromycin Offers New Hope Against Drug-Resistant Pneumonia
• Nafithromycin, India's first indigenous antibiotic, targets drug-resistant community-acquired bacterial pneumonia (CABP) and offers a new treatment option.
• Developed by BIRAC and Wockhardt, Nafithromycin boasts a three-day treatment regimen and is reportedly ten times more effective than azithromycin.
• Clinical trials show a 96.7% cure rate with superior safety, minimal side effects, and broad-spectrum action against typical and atypical bacteria.
• Awaiting final approval, Nafithromycin may be integrated into India's Ayushman Bharat scheme for increased accessibility and affordability.
© Copyright 2025. All Rights Reserved by MedPath